Cancer | Methods | Classical (N = 50) | Mesenchymal (N = 48) | Neural (N = 30) | Proneural (N = 48) |
---|---|---|---|---|---|
GB | SRF50 | 70.0% | 81.3% | 73.3% | 93.8% |
Single RF | 64.0% | 77.1% | 80.0% | 91.7% | |
Verhaak et al. | 88.0% | 91.7% | 50.0% | 100.0% | |
ANOVA | 88.0% | 91.7% | 40.0% | 100.0% | |
Top 50 ANOVA | 66.0% | 83.3% | 73.3% | 87.5% | |
Basal-Like (N = 18) | HER2 (N = 11) | Luminal A (N = 20) | Luminal B (N = 32) | ||
BC | SRF50 | 100.0% | 63.6% | 80.0% | 84.4% |
Single RF | 88.9% | 72.7% | 55.0% | 87.5% | |
Parker et al. | 100.0% | 54.5% | 90.0% | 93.8% | |
ANOVA | 100.0% | 36.4% | 85.0% | 93.8% | |
Top 50 ANOVA | 100.0% | 63.6% | 75.0% | 84.4% | |
C1 (N = 42) | C2 (N = 25) | C4 (N = 23) | C5 (N = 18) | ||
OC | SRF50 | 97.6% | 88.0% | 73.9% | 94.4% |
Single RF | 97.6% | 88.0% | 78.3% | 83.3% | |
Tothill et al. | 97.6% | 88.0% | 87.0% | 88.9% | |
ANOVA | 100.0% | 88.0% | 78.3% | 88.9% | |
Top 50 ANOVA | 95.2% | 88.0% | 73.9% | 83.3% |